Avid Bioservices Inc (CDMO)

[biopharm]

You have failed 100% in my view. Why would you try to pass off the collaboration/partnership Peregrine Pharmaceuticals has with AstraZeneca as something less than a partnership?

CJ's post below is a must read and explains it all perfectly. This post puts to rest the misinformation.

http://investorshub.advfn.com/boards/manage_msg.asp?message_id=119295823

-----------------------------------------------

It seems you are completely off track in your legacy way of thinking here. If Peregrine would have been required to pay for the cost of the drug ( up to $100k ) per patient in a trial then they would have had to raise that money possibly via an ATM sale, BUT THEY DO NOT HAVE TO NOW, because AstraZeneca is paying 100% of the cost of treatment for all patients.

This is why Peregrine CEO Steven King made reference to how much they are saving in cash.

SK 12-15-15/BioWorld on AZN: “We save probably as much as we're spending because of the cost of these drugs.”

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119232230

Next, anyone paying attention knows 100% that AstraZeneca would not just volunteer their network and expertise and partnership and just give Peregrine a non-exclusive without a fight.

Peregrine had the leverage in those negotiations...huh? : )

Big Pharma loves to tie up small biotechs with exclusive deals because that is just another tactic to slow down the competition.

Peregrine is not about to slow down.

Bavituximab is in the hands of dozens of collaborators and it is much too late to hold it back now.

Combinations are fast approaching and Bavituximab will have to be included to even have a chance for the most optimal, robust, immune response.

David Berman ex-BMS knows this very well : )